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Abstract
As life expectancy greatly increases in persons with hemophilia (PWH), more age-related diseases such as cancer
and cardiovascular disease (CVD) emerge among this patient group. The aim of this study was to review the
available evidence on the epidemiology of CVD events, and incidence and survival of cancer in PWH. The
prevalence of CVD events among PWH seems to be similar to that of the general population. Some known risk
factors for the event, including aging, hypertension, and hyperlipidemia, are also associated with its occurrence in
PWH. There is no evidence showing occurrence of the event directly to clotting factor concentrate administration.
On the other hand, the incidence of non-virus related cancer seems to be higher in PWH than the general
population. In addition, PWH with cancer were younger at the time of diagnosis. In regards to hemophilia effect on
cancer prognosis, further basic and large-scale prospective studies are urgently needed.
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Background
The challenges in hemophilia care change with time. Life
expectancy was increased in persons with hemophilia
(PWH) after the introduction of clotting factor concen-
trates (CFCs) in the 1970s. But complications due to
hepatitis C virus (HCV) or human immunodeficiency
virus (HIV) contaminated clotting factor products re-
sulted in the main health problem in the 1980s and
1990s [1, 2]. As recombinant CFCs commercialized, life
expectancy in PWH nearly approaches the general popu-
lation [3, 4]. However, clinical physicians are facing new
challenges, mostly age-related disease [5, 6]. Older PWH
are at risk for developing aging comorbidities, such as
cardiovascular disease (CVD) and cancer. Hemophilia is
a hereditary bleeding disorder that results from the
absence or deficiency of clotting factor. It is plausible
that a hypocoagulable state, such as that present in
PWH or hemophilia carriers, have a protective effect
on thrombus formation, which precipitates CVD
events [7, 8]. And, a presumed protection of these
inherited bleeding disorders against cancer progres-
sion is particularly intriguing [9]. However, to date,
there are few cohort studies involving PWH with
CVD and cancer, and the risk for these two age-
related comorbidities in PWH is often left to physi-
cian’s discretion. In addition, rare research is focused
on how CFCs affect these two comorbidities. There is
considerable interest in the complex interaction be-
tween bleeding tendency and age-related disease
among PWH. This review aimed to evaluate preva-
lence of CVD events, and cancer incidence and sur-
vival among PWH in comparison with the general
population. In addition, the association between CFC
use and the two age-related diseases was investigated.
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Cardiovascular diseases in hemophilia patients
Since hemophilia A and B patients are absence or defi-
ciency of coagulation factors, it is plausible that defi-
ciency of coagulation factor VIII or IX exerts a
protective effect on the development of CVD events.
However, CVD events are increasingly being reported in
the hemophilia populations. It is probably caused by sig-
nificant increase in the life expectancy of PWH. Several
studies have found that the incidence of or mortality due
to CVD events in PWH was lower than that in the gen-
eral population [3, 10–13]. However, some studies have
shown that PWH have a similarly high prevalence of
atherosclerotic plaques as the general population [14–16].
Moreover, in a systematic review, mortality due to CVD
was found to be non-significantly reduced in PWH as
compared with the general population [17].
A nationwide analysis conducted to compare CVD
events between PWH and general population in Taiwan
was reported in 2015 [18]. The data was obtained from
the catastrophic illness lists of the National Health
Insurance Research Database (NHIRD). Data of the
general male population for comparison with the
hemophilia group was retrieved from the Longitudinal
Health Insurance Database by matching the birth
month. The population-based survey showed that the
prevalence rate of CVD events including ischemic heart
disease, ischemic stroke and peripheral arterial disease is
similar between PWH and the general population. How-
ever, the result on the prevalence of CVD events be-
tween PWH and general population is inconsistent in
the literature. In 2011, Biere-Rafi et al. reported that the
expected risk of CVD events among PWH is comparable
to that in the general population [17]. A study con-
ducted in the Netherlands and the UK corroborates this
result [19]. However, several cohort studies on the
prevalence of CVD, even all in the United States, are
contradictory. In 2005, Kullarni et al. reported that
PWH with ischemic heart disease had lower hospital dis-
charge rate than those of an age-matched population
without coagulation disorders [10]. Ragni et al. reported
that the prevalence of CVD in PWH was similar with
that of the general population [20]. Another study con-
ducted by Sharathkumar et al. found that PWH were
almost twice as likely to have CVD, compared with indi-
viduals without hemophilia [21]. The data on survey of
2560 USA males with hemophilia A patients showed
similar findings [22]. There are several possible explana-
tions for the discrepancy among these studies. First, the
extent to which age-matched reference data was prop-
erly applied may have varied among these studies.
Second, the definition of CVD in these studies was
different. Some cardiovascular problems including cardio-
myopathy, valvular heart disease and rhythm disturbance
were defined as CVD events. Finally, the proportion of
PWH with severe hemophilia, whose low level of clotting
factor has a protective effect on CVD occurrence and may
have influenced the results, was diverse and not analyzed
separately.
There are also few data on investigation of the risk
factors for CVD events among PWH [23, 24]. In
addition, few studies have investigated whether CFC use
contributes to the development of CVD events in the
hemophilia population. In our survey of 1105 PWH col-
lected from Taiwan’s NHIRD between 1997 and 2011,
sixty-four arterial thrombotic events, including 32 with
ischemic heart disease, 27 with ischemic stroke, and 7
with peripheral arterial occlusive disease, and 5 venous
thrombotic events were identified [25]. Less CFC use
was found in those PWH with than without CVD
events. In addition, PWH who needed replacement ther-
apy had a lower risk of CVD events than those who did
not need, with a hazard ratio (95 % CI) of 0.41 (0.21–
0.81). The results could be interpreted as the occurrence
of CVD events inversely related to the severity of
hemophilia. Furthermore, analysis of the case-crossover
design showed the amount of CFC use in PWH with
CVD events was not increased prior to the event. Based
on the result of the nationwide and population-based re-
port, no evidence support CFC administration in PWH
is a risk factor for CVD occurrence. Another interesting
issue in terms of CVD events not well addressed now is
if there is any difference between PWH who are on
purely recombinant clotting factors and plasma-derived
clotting factors. Purity of clotting factor VIII or factor IX
prothrombin complex usage may contribute to the risk
of CVD events.
Obesity has been reported to be associated with CVD
events in the general population [26, 27]. In addition, it
is an emerging issue contributing to chronic disease and
disability, particularly as the life expectancy of PWH
now more closely matches that of their healthy peers.
Interestingly, obesity was found to be not a risk factor
for CVD events in an analysis of 185 adult hemophil-
iacs [21]. In our hemophilia cohort, we also found
that PWH with obesity did not have a greater risk for
CVD events.
Aging is also a known risk factor for CVD events.
Interestingly, a population-based analysis has shown
that the mean age at diagnosis of CVD events among
PWH was younger than that in the general population:
49.0 (95 % CI, 43.6–54.5) and 55.8 years (95 % CI, 54.5–
57.0), P = 0.019 [18]. Although it is probably because
hemophilia is a hereditary disorder which is diagnosed
early with close follow-up and hence picking up CVD
events, these results are suggestive of the need for
earlier screening for the age-related comorbidities
among PWH.
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Occurrence and survival of cancer in Hemophilia patients
Malignancies, just like CVD events, emerge as one of
the important causes of morbidity and mortality in
PWH nowadays [9, 28–38]. In the previous decade, most
reports focused on the epidemiology and outcome of
blood-borne cancers in the hemophilia patients group,
as the incidence of HBV, HCV and HIV infection were
high among them. In recent decades, some animal
models imply that inherited coagulation disorders like
hemophilia can inhibit metastasis, but substitution of co-
agulation factors seems to support metastasis [39]. In
addition, clinical investigation has suggested the effect of
hemophilia on cancer-related mortality. Since the re-
combinant CFCs are widely introduced, physicians are
paying attention to non-virus related malignancies.
However, there was limited data focusing on the
epidemiology of non-virus related malignancy in PWH
[9, 30]. In 2000, Soucie et al found non HIV- or liver-
related cancer caused 2.2 folds of death adjusted with
standard mortality rate [40]. In 2009, Miesbach W et al
also found that the prevalence of cancer in elderly PWH
was four times higher than in the age matched general
population when hepatocellular carcinoma (HCC) was
excluded [30]. However, Plug I et al found that when
HCC was excluded, malignancy related death did not in-
crease among PWH [41]. In contrast, Walker et al. re-
ported that among HIV negative PWH in Canada, after
excluding liver cancer and lymphoma, cancer related
deaths were less than expected [1]. Furthermore, in a
systemic review by Miesbach et al, when HIV and hepa-
toma were excluded, standard mortality rate of PWH are
decreased [9]. Generally, the discrepancy of prevalence
and outcome of cancer may be caused by conduction in
different periods, which would be affected by the wide-
spread introduction of CFCs and modern comprehensive
hemophilia care. Importantly, all these studies are of
insufficient sample size, and therefore carry a high risk
of type 1 or 2 errors.
We conducted a nationwide and population-based
analysis on the occurrence and survival of cancer in
PWH between 1997 and 2010 [42]. The data in the co-
hort study showed that the prevalence of cancers among
PWH was higher than general population (odd ratio
2.42, 95 % CI 1.74–3.35). After excluding patients with
HIV or HCV infection, there was still significant differ-
ence between hemophilia and general group (odd ratio
1.66, 95 % CI 1.06–2.59). In addition, interestingly,
PWH were diagnosed cancers at a much younger age. It
is plausible that there shall be other causes of cancer
progression among PWH. Frequent radiation exposure
from diagnostic image and intraarticular therapy in
PWH may play a role, as it was documented that higher
radiation accumulation might increase cancer occur-
rence and progression [43]. This hypothesis still needs
further prospective observation trials to prove. Repeated
bleeding and chronic inflammation from hemophiliac
Before cancer diagnosis After cancer diagnosis
IU
Fig. 1 Comparison of annual amount of clotting factor used before and after cancer diagnosis among 33 hemophilia A patients (p = 0.0002)
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arthropathy has been linked to cancer induction and
metastasis [44, 45]. For PWH, this can be one important
factor affecting cancer progression, but no direct link
was proven yet.
In addition, the study showed that PWH had similar
survival time with the general population after acquiring
cancer. Factor VIII deficiency and following reduced
thrombin activation in PWH can lead to reducing cancer
progression in several vitro studies [46, 47]. In mice ex-
periments, Langer R et al have proved that clotting fac-
tor VIII can enhance tumor metastasis, and reduced by
a direct thrombin inhibitor [39]. It is still not known
whether long-term treatment with CFCs can intensify
thrombin induced metastases, or the replacement dosage
is too low to generate such effect among PWH [9].
Therefore, we did further investigation on the average
amount of clotting factor use before and after cancer
diagnoses (Fig. 1). Among 33 patients with hemophilia A
and cancer, there were 22 patients who needed replace-
ment therapy before cancer diagnosed. The remaining
11 patients did not need replacement therapy, and
started replacement afterwards. We compared the aver-
age amount of clotting factor VIII in these PWH used
before and after cancer diagnosis, and found a significant
increase in demand. It is plausible that therapeutic surgi-
cal procedures that warrant CFC coverage or any bleed-
ing complications following chemotherapy requiring
CFC replacement contributes to the increase in demand
of CFC after cancer diagnosis. However, this leads us to
consider about whether the intensity of CFC use after
PWH acquiring cancer is associated with prognosis of
cancer. Further research is needed to elucidate whether
CFC administration will lead to cancer progression in
human patients. And, a large cohort study is needed to
investigate that whether large amount of excess CFC use
in PWH with cancer would lead no protection of clot-
ting deficiency from cancer treatment can lead to cancer
progression.
Conclusions
Studies on age-related comorbidities in PWH are in-
creasingly reported. To date, there is little large-scale
and prospective survey involving epidemiology of PWH
with comorbidities of CVD events and cancer, and the
risk for these aging diseases in PWH is often left to phy-
sician’s discretion. The current evidence showed the
prevalence of CVDs among PWH seems to be compar-
able to that of the general population. Some known risk
factors for CVD events, including aging, hypertension,
and hyperlipidemia are also associated with the occur-
rence of CVD events in PWH. There is no evidence
showing occurrence of the event directly to CFC admin-
istration. In the other hand, the incidence of non-virus
related cancer seems to be higher in PWH than the
general population. In addition, PWH with cancer were
younger at the time of diagnosis. In regards to
hemophilia effect on cancer prognosis, further basic and
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